What is the share price of Akums Drugs and Pharmaceuticals Ltd (AKUMS) today?
The share price of AKUMS as on 6th August 2026 is ₹662.55. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Akums Drugs and Pharmaceuticals Ltd (AKUMS) share?
The past returns of Akums Drugs and Pharmaceuticals Ltd (AKUMS) share are- Past 1 week: 0.08%
- Past 1 month: 5.25%
- Past 3 months: 19.99%
- Past 6 months: 48.25%
- Past 1 year: 36.03%
- Past 3 years: N/A%
- Past 5 years: -16.79%
What are the peers or stocks similar to Akums Drugs and Pharmaceuticals Ltd (AKUMS)?
The peers or stocks similar to Akums Drugs and Pharmaceuticals Ltd (AKUMS) include:What is the dividend yield % of Akums Drugs and Pharmaceuticals Ltd (AKUMS) share?
The current dividend yield of Akums Drugs and Pharmaceuticals Ltd (AKUMS) is 0.45.What is the market cap of Akums Drugs and Pharmaceuticals Ltd (AKUMS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Akums Drugs and Pharmaceuticals Ltd (AKUMS) is ₹10198.13 Cr as of 6th August 2026.What is the 52 week high and low of Akums Drugs and Pharmaceuticals Ltd (AKUMS) share?
The 52-week high of Akums Drugs and Pharmaceuticals Ltd (AKUMS) is ₹714.70 and the 52-week low is ₹409.30.What is the PE and PB ratio of Akums Drugs and Pharmaceuticals Ltd (AKUMS) stock?
The P/E (price-to-earnings) ratio of Akums Drugs and Pharmaceuticals Ltd (AKUMS) is 39.96. The P/B (price-to-book) ratio is 3.06.Which sector does Akums Drugs and Pharmaceuticals Ltd (AKUMS) belong to?
Akums Drugs and Pharmaceuticals Ltd (AKUMS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Akums Drugs and Pharmaceuticals Ltd (AKUMS) shares?
You can directly buy Akums Drugs and Pharmaceuticals Ltd (AKUMS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Akums Drugs and Pharmaceuticals Ltd
AKUMS Share Price
NSE₹662.550.53% (-3.55)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
AKUMS Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
AKUMS Performance & Key Metrics
AKUMS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 39.96 | 3.06 | 0.45% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.38 | 5.86 | 0.51% |
100%
Analysts have suggested that investors can buy this stock
from 3 analysts
Price Upside
Earnings Growth
Rev. Growth
AKUMS Company Profile
Akums Drugs and Pharmaceuticals is pharmaceutical contract development and manufacturing company.
SUNPHARMA
PE Ratio
40.55
40.55
1Y Return
22.30%
22.30%
Buy Reco %
93.33
93.33
TORNTPHARM
PE Ratio
87.91
87.91
1Y Return
40.63%
40.63%
Buy Reco %
82.14
82.14
CIPLA
PE Ratio
30.38
30.38
1Y Return
0.65%
0.65%
Buy Reco %
62.86
62.86
ZYDUSLIFE
PE Ratio
22.19
22.19
1Y Return
18.79%
18.79%
Buy Reco %
53.57
53.57
LUPIN
PE Ratio
20.47
20.47
1Y Return
28.79%
28.79%
Buy Reco %
54.29
54.29
AKUMS Sentiment Analysis
AKUMS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
AKUMS Stock Summary · May 2026
Management characterized FY26 as resilient top‑line growth with strong cash conversion, reporting revenue of INR 4,359 crore and operating cash flow of INR 1,181 crore, driven by a strengthening CDMO franchise even as the API business lagged. CDMO revenue and margins benefited from higher capacity utilization and facility ramp‑ups, with material H2 volume growth (north of 25%) and early European supplies, while new injectable, Penem and oral‑solids assets are in advanced stages of commercialization. In contrast, cephalosporin/API price erosion compressed volumes and led to an API EBITDA loss, prompting cost actions, portfolio rationalization toward non‑cephalosporin and regulated‑market exports, and a target of monthly API EBITDA positivity even though FY27 may still report a net loss. Management highlighted secured international contracts alongside EU‑accredited Plant 2 activity and planned Zambia supply flows from Indian facilities, recommended a dividend package, and emphasized prioritizing incremental cash for organic and inorganic growth, while expecting base margins to stay broadly steady with potential upside as fixed contracts scale.
AKUMS Stock Growth Drivers
AKUMS Stock Growth Drivers
5CDMO commercial momentum and regulated‑market expansion
The CDMO business is demonstrating clear commercial traction, with FY26 revenue of INR3,485 crore (+8.6%
Profitability recovery and margin expansion
Reported and adjusted profitability metrics improved notably through FY26 and Q4, reflecting operating leverage and
AKUMS Stock Challenges
AKUMS Stock Challenges
9Adverse operating environment: sharp API price erosion and weak domestic volumes
The company faced an adverse H1 FY26 operating environment driven by a sharp erosion in
API segment: sustained losses, revenue decline and capacity under‑utilization
The API business underperformed through the year, with persistent pricing pressure (not limited to cephalosporins)
AKUMS Forecast
AKUMS Forecasts
Price
Revenue
Earnings
AKUMS Share Price Forecast
AKUMS Share Price Forecast
2026
Current
₹662.55
Baseline
Forecast for Aug 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹662.55
Baseline
Forecast for Aug 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
AKUMS Company Revenue Forecast
AKUMS Company Revenue Forecast
2026
Current
₹4.49
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹4.49
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
AKUMS Stock EPS (Earnings Per Share) Forecast
AKUMS Stock EPS (Earnings Per Share) Forecast
2026
Current
₹16.67
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹16.67
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
AKUMS
AKUMS
Income
Balance Sheet
Cash Flow
Quarterly Normal View
AKUMS Income Statement
AKUMS Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,092.67 | 954.67 | 1,025.66 | 1,050.26 | 1,029.75 | 1,081.31 | 1,050.76 | 1,049.90 | 1,193.92 | 1,193.17 | ||||||||||
Operating & Other expenses | 989.40 | 941.22 | 891.10 | 911.90 | 889.05 | 961.63 | 895.06 | 923.05 | 1,030.96 | 1,007.94 | ||||||||||
EBITDA | 103.27 | 13.45 | 134.56 | 138.36 | 140.70 | 119.68 | 155.70 | 126.85 | 162.96 | 185.23 | ||||||||||
| Depreciation/Amortization | 31.55 | 33.95 | 34.06 | 34.87 | 44.52 | 40.00 | 36.92 | 37.86 | 39.65 | 40.12 | ||||||||||
| PBIT | 71.72 | -20.50 | 100.50 | 103.49 | 96.18 | 79.68 | 118.78 | 88.99 | 123.31 | 145.11 | ||||||||||
| Interest & Other Items | 12.44 | 12.38 | 13.02 | 11.90 | 5.13 | 4.54 | 23.14 | 23.30 | 23.74 | 23.89 | ||||||||||
| PBT | 59.28 | -32.88 | 87.48 | 91.59 | 91.05 | 75.14 | 95.64 | 65.69 | 99.57 | 121.22 | ||||||||||
| Taxes & Other Items | -134.42 | 8.44 | 27.32 | 26.39 | 25.88 | -72.48 | 32.17 | 24.89 | 33.25 | 36.60 | ||||||||||
| Net Income | 193.70 | -41.32 | 60.16 | 65.20 | 65.17 | 147.62 | 63.47 | 40.80 | 66.32 | 84.62 | ||||||||||
| EPS | 13.21 | -2.89 | 4.21 | 4.37 | 4.26 | 9.64 | 4.15 | 2.66 | 4.33 | 5.53 |
AKUMS Company Updates
AKUMS Stock Peers
AKUMS Past Performance & Peer Comparison
AKUMS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Akums Drugs and Pharmaceuticals Ltd | 39.96 | 3.06 | 0.45% |
| Sun Pharmaceutical Industries Ltd | 40.55 | 5.55 | 0.82% |
| Torrent Pharmaceuticals Ltd | 87.91 | 10.82 | 0.68% |
| Cipla Ltd | 30.38 | 3.41 | 0.89% |
AKUMS Stock Price Comparison
Compare AKUMS with any stock or ETFCompare AKUMS with any stock or ETF
AKUMS
AKUMS Holdings
AKUMS Shareholdings
AKUMS Promoter Holdings Trend
AKUMS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
AKUMS Institutional Holdings Trend
AKUMS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
AKUMS Shareholding Pattern
AKUMS Shareholding Pattern
AKUMS Shareholding History
AKUMS Shareholding History
Foreign Institutions
Mutual Funds Invested in AKUMS
Mutual Funds Invested in AKUMS
No mutual funds holding trends are available
Top 5 Mutual Funds holding Akums Drugs and Pharmaceuticals Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.5480% | Percentage of the fund’s portfolio invested in the stock 1.72% | Change in the portfolio weight of the stock over the last 3 months 0.16% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 27/61 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3627% | Percentage of the fund’s portfolio invested in the stock 0.97% | Change in the portfolio weight of the stock over the last 3 months 0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 79/100 (-7) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3323% | Percentage of the fund’s portfolio invested in the stock 2.05% | Change in the portfolio weight of the stock over the last 3 months 0.22% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 19/47 (-1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing AKUMS stock
smallcases containing AKUMS stock
Looks like this stock is not in any smallcase yet.
AKUMS Events
AKUMS Events
AKUMS Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
AKUMS Dividend Trend
No dividend trend available
AKUMS Upcoming Dividends
AKUMS Upcoming Dividends
No upcoming dividends are available
AKUMS Past Dividends
AKUMS Past Dividends
Cash Dividend
Ex DateEx DateJul 3, 2026
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Jul 3, 2026
Cash Dividend
Ex DateEx DateJul 3, 2026
Special
Special | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jul 3, 2026
AKUMS Stock News & Opinions
AKUMS Stock News & Opinions
Articles & Videos
Corporate
Corporate
Akums Drugs to review quarterly financial results at a board meeting on August 8Akums Drugs and Pharmaceuticals Limited will hold a board meeting on Saturday, August 8, 2026, to consider and approve the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, according to a regulatory filing.
1 day agoCapital Market - Live
Corporate
Corporate
Akums Drugs & Pharmaceuticals resumes production at Haridwar sitesAkums Drugs & Pharmaceuticals announced that all manufacturing operations at the affected sites of the Company and its Subsidiaries, situated in the state of Uttarakhand, have been successfully resumed at 100% operations capacity with effect from 18 May 2026. The partial disruption in production at Haridwar sites lasted for four days which resulted in delayed supply of approx. Rs 20 crore.
2 months agoCapital Market - Live
Corporate
Corporate
Akums reports temporary disruptions in operations due to labour unrestAkums Drugs & Pharmaceuticals announced that certain manufacturing sites at Haridwar have been impacted due to labour unrest at SIDCUL industrial area in Haridwar on 14 May 2026. The unrest has resulted in temporarily disruption of operations and active measures are being taken to normalize the operations.
2 months agoCapital Market - Live
Corporate
Corporate
Board of Akums Drugs & Pharmaceuticals recommends special dividendAkums Drugs & Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 14 May 2026, inter alia, have recommended the special dividend of Rs 2 per equity Share (i.e. 100%) , subject to the approval of the shareholders.
2 months agoCapital Market - Live
Corporate
Corporate
Board of Akums Drugs & Pharmaceuticals recommends final dividendAkums Drugs & Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 14 May 2026, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 50%) , subject to the approval of the shareholders.
2 months agoCapital Market - Live
Corporate
Corporate
Akums Drugs & Pharmaceuticals schedules AGMAkums Drugs & Pharmaceuticals announced that the 22th Annual General Meeting(AGM) of the company will be held on 10 July 2026.
2 months agoCapital Market - Live
Corporate
Corporate
Akums Drugs & Pharmaceuticals schedules board meetingAkums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 May 2026.
2 months agoCapital Market - Live
Earnings
Earnings
Akums Drugs & Pharmaceuticals consolidated net profit rises 1.75% in the December 2025 quarterNet profit of Akums Drugs & Pharmaceuticals rose 1.75% to Rs 66.32 crore in the quarter ended December 2025 as against Rs 65.18 crore during the previous quarter ended December 2024. Sales rose 14.76% to Rs 1159.59 crore in the quarter ended December 2025 as against Rs 1010.41 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1159.591010.41 15 OPM %12.6612.01 - PBDT157.45130.79 20 PBT117.8086.27 37 NP66.3265.18 2 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Akums Drugs & Pharmaceuticals announces board meeting dateAkums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 February 2026.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Akums Drugs & Pharmaceuticals receives EU-GMP approval for Haridwar Plant 1& 2Akums Drugs & Pharmaceuticals has received European GMP certificates for its two facilities, Plant 1 and Plant 2, both located at Haridwar, Uttarakhand. While the certification for Plant 1 represents a renewal of its existing EU-GMP approval, Plant 2 has received EU-GMP certification for the first time. Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 10.34%, vs industry avg of 12.48%
Over the last 5 years, market share decreased from 0.97% to 0.88%
Over the last 5 years, net income has grown at a yearly rate of 15.77%, vs industry avg of 10.55%